NDA 202276 · Vivus LLC
Stendra
Avanafil · Oral
NovelLast checked: Nov 20, 2026Latest source record: Oct 18, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Apr 27, 2012
Approved uses
4
Original approval plus efficacy supplements
Registered trials
24
7 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 18, 2022 Supplement 20 · Efficacy LetterLabel
- Aug 3, 2018 Supplement 18 · Efficacy LabelLetter
- Sep 17, 2014 Supplement 5 · Efficacy LabelLetter
- Apr 27, 2012 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
3 products under this application
- STENDRA · AVANAFIL 100MG · TABLET, ORAL · Prescription · TE AB
- STENDRA · AVANAFIL 200MG · TABLET, ORAL · Prescription · TE AB
- STENDRA · AVANAFIL 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Avanafil" as an intervention, any sponsor and status, largest first.
- Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile DysfunctionPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00853606 · 712 participants · Start Mar 2009 · Primary completion Apr 2010
Drug: avanafil · For: Erectile Dysfunction
Sites: Birmingham, Alabama; Homewood, Alabama; Tucson, Arizona · 40 sites in all
- Research Evaluating an Investigational Medication for Erectile Dysfunction - General EDPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00790751 · 646 participants · Start Nov 2008 · Primary completion Aug 2009
Drug: placebo; avanafil and 2 more · For: Erectile Dysfunction
Sites: Birmingham, Alabama; Homewood, Alabama; Tucson, Arizona · 41 sites in all
- Research Evaluating a PDE5 Inhibitor for Erectile DysfunctionPivotal-lookingCompleted
VIVUS LLCIndustry
NCT01698684 · 440 participants · Start Sep 2012 · Primary completion Apr 2013
Drug: Placebo; Avanafil 100 mg and 1 more · For: Erectile Dysfunction
Sites: Jupiter, Florida; Raleigh, North Carolina; Wilmington, North Carolina
- Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)Pivotal-lookingCompleted
VIVUS LLCIndustry
NCT00809471 · 390 participants · Start Dec 2008 · Primary completion Feb 2010
Drug: placebo; avanafil and 1 more · For: Erectile Dysfunction
Sites: Birmingham, Alabama; Homewood, Alabama; Tucson, Arizona · 39 sites in all
- Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-ProstatectomyPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00895011 · 298 participants · Start Apr 2009 · Primary completion Apr 2011
Drug: Placebo; Avanafil and 1 more · For: Erectile Dysfunction
Sites: Phoenix, Arizona; Laguna Hills, California; Los Angeles, California · 51 sites in all
- Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of AvanafilPivotal-lookingCompleted
JW PharmaceuticalIndustry
NCT00903981 · 208 participants · Start Mar 2009 · Primary completion Oct 2009
Drug: Avanafil; Avanafil and 1 more · For: Erectile Dysfunction
Sites: Jeonju, South Korea
- This Study is to Evaluate the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction.Pivotal-lookingCompleted
JW PharmaceuticalIndustry
NCT01705197 · 195 participants · Start Feb 2012 · Primary completion Apr 2013
Drug: Avanafil 100 or 200mg · For: Erectile Dysfunction
Sites: Seoul, South Korea
- Efficacy and Tolerability Study of Avanafil in RussiaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02503306 · 189 participants · Start Jul 2015 · Primary completion Mar 2016
Drug: AVANAFIL; placebo · For: Sexual Function and Fertility Disorders NEC-Erectile Dysfunction
Sites: Moscow, Russia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Avanafil for male erectile dysfunction: a systematic review and meta-analysis.
Cui YS, Li N, Zong HT, et al. · Asian J Androl 2014 · Meta-Analysis, Systematic Review
- Avanafil for the Treatment of men With Erectile Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Li J, Peng L, Cao D, et al. · Am J Mens Health 2019 · Meta-Analysis, Systematic Review
- The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis.
Wang H, Yuan J, Hu X, et al. · Curr Med Res Opin 2014 · Comparative Study, Systematic Review
- Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T · Sex Med Rev 2016 · Systematic Review
- The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.
Corona G, Rastrelli G, Burri A, et al. · Expert Opin Drug Saf 2016 · Comparative Study, Meta-Analysis
- Associations between phosphodiesterase type 5 inhibitors and vascular function: a systematic review and meta-analysis on randomized-controlled trials.
Zhang Y, Peng H, Xin S, et al. · Syst Rev 2025 · Systematic Review, Meta-Analysis
Sponsor: Vivus LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.